Genmab — Juni 2014
-
Daratumumab opdateret til 'active, not recruiting' - http://clinicaltrials.gov/ct2/show/NCT01985126?term=daratumumab&rank=1
-
celsius har du læst Helges artikeluddrag fra "Dagens Medicin"? http://www.proinvestor.com/boards/69141/Daratumumab-er-meget-effektiv-mod-knoglekraeft
-
Lodtrækning er hvis en dårlig oversættelse af det vi kalder randomisering
-
altså et phase III studie hvor patienterne "randomiseres" dvs. fordeles i 2 arme hvor den ene får Lenalidomide+Dex og de andre for Dara+LenDex
-
mht. det link Gentogen henviste til er det jo bare at Dara pivotalstudie nu også står som fuld rekruteret på CT
-
det tror jeg men tror også de er indeholdt i deres nuværende guidiance
-
Der ville stå: "Not yet recruiting" hvis studiet ikke var startet med at rekruttere endnu
-
du fandt selv svaret

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind